Planning your compound's pathway to the clinic

Navigating the pathway to first-in-human (FIH) clinical trials for a new chemical entity (NCE) is a highly complex process for drug manufacturers. 

Through Pathway to Clinic®, Recipharm, in collaboration with Clinical Trial Consultants (CTC), works with drug development companies to reduce the complexity of their FIH projects and recognises the pattern of challenges that are presented as new formulations progress through the development cycle.

Discover how by registering below to download the full white paper.
/sites/default/files/media/Whitepaper_Planning-your-compounds-pathway-to-clinic.pdf
False
True